{"entity":{"id":"cr-002","kind":"drug","name":"CR-002","aka":[],"tldr":"CR-002 is an experimental antibody-drug conjugate from Crescent Biopharma, in phase 1 trials for non-small cell lung cancer, head and neck squamous cell carcinoma and advanced solid tumours.","summary":"CR-002 is an antibody-drug conjugate (topoisomerase inhibitor payload) from Crescent Biopharma. An antibody-drug conjugate that uses a highly internalising PD-L1 antibody to carry a topoisomerase inhibitor payload into tumour cells, with a linker designed to be cleaved inside the cell. Its furthest stage is phase 1, for non-small cell lung cancer, head and neck squamous cell carcinoma and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. FDA cleared the IND; the APOLLO phase 1/2 trial (NCT07909031) is listed as recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Crescent Biopharma: crescentbiopharma.com","url":"https://www.crescentbiopharma.com/pipeline"},{"label":"Crescent Biopharma: crescentbiopharma.com","url":"https://www.crescentbiopharma.com/pipeline"},{"label":"Crescent Biopharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07909031"},{"label":"ClinicalTrials.gov: trials of CR-002","url":"https://clinicaltrials.gov/search?intr=CR-002"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","head-and-neck","metastatic-cancer"],"sections":[],"technologies":[],"targets":["pdl1"],"drugs":[],"companies":["crescent-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07909031"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CR-002","modality":"Antibody-drug conjugate (topoisomerase inhibitor payload)","mechanism":"An antibody-drug conjugate that uses a highly internalising PD-L1 antibody to carry a topoisomerase inhibitor payload into tumour cells, with a linker designed to be cleaved inside the cell.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cr-002/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"crescent-biopharma","kind":"company","name":"Crescent Biopharma","route":"/companies/crescent-biopharma/"}],"trial":[{"id":"nct07909031","kind":"trial","name":"CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07909031/"}]}}